MET and colorectal carcinoma: The other + dMMR subgroup largely consisted of patients with all‐wild‐type CRC or patients with mutations in BRAF and/or PIK3CA, whereas, the other + pMMR subgroup mainly consisted of patients with mutations in RAS (NRAS, KRAS) and/or MET.